Celldex Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.174 million compared to USD 0.685 million a year ago. Net loss was USD 23.05 million compared to USD 16.54 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 0.42 a year ago. Diluted loss per share from continuing operations was USD 0.49 compared to USD 0.42 a year ago.